From drought to demand: Biotech IPOs roar back with Kailera and Alamar
- Posted on April 18, 2026
- By Fortune
- 0 Views
- 1 min read
From drought to demand: Biotech IPOs roar back with Kailera and Alamar

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks up most venture dollars.